With bond yields swinging on inflation fears and heavy government debt issuance, investors face a harder time relying on broad markets alone for growth. That puts more focus on individual companies where insiders already have significant skin in the game and where analysts and management see room to expand. This article highlights three fast growing stocks with high insider ownership from our screener that fit that profile.
The stocks covered below are just a sample from this theme. The full screen surfaced 102 more companies with similarly strong growth stories and insider alignment that are not covered here. To identify and analyze the highest conviction ideas across that full set, go straight to the Fast Growing Stocks With High Insider Ownership screener.
Mesoblast (ASX:MSB)
Overview: Mesoblast is a Melbourne based biotech that develops regenerative medicine therapies built on mesenchymal lineage cells, with its lead product remestemcel L in Phase III trials for severe inflammatory diseases, chronic heart failure and chronic low back pain. This late stage pipeline is the main reason Mesoblast aligns with the Fast Growing Stocks With High Insider Ownership theme, as it concentrates potential growth in a handful of cell therapy programs.
Operations: Mesoblast currently generates revenue primarily from the development of its cell technology platform for commercialization, which contributed about $65 million in the most recent period.
Market Cap: A$3.1 billion
Mesoblast appeals to growth focused investors because its mesenchymal stromal cell platform already supports an approved therapy in Ryoncil, while multiple Phase III programs, including rexlemestrocel L for chronic low back pain and heart failure, aim at very large patient populations. Analysts currently expect strong revenue and earnings growth over the coming years, although those forecasts rely on successful trial results, regulatory decisions and further uptake of Ryoncil. The company remains loss making and funds late stage trials with external borrowings, so delays or weak data could increase financing risk. If Mesoblast executes on its pipeline and manages reimbursement and competition carefully, the gap between today’s cash burn and analysts’ long term earnings expectations could narrow in a meaningful way.
Mesoblast’s late stage cell therapy pipeline could be the missing link between today’s cash burn and tomorrow’s potential revenue curve. Before you assume the story is straightforward, read the analyst forecasts for Mesoblast that hints at what happens if one key pillar shifts.
Build your own high growth and insider backed shortlist
Mesoblast and the other two stocks in this article all came from the same Simply Wall St screener, which you can easily adapt to your own style. Use our customisable Screener to mix filters like valuation, future growth, balance sheet strength and risks, or start with one of our curated Investing Ideas.
Telix Pharmaceuticals (ASX:TLX)
Overview: Telix Pharmaceuticals is a radiopharmaceutical company that develops and commercialises precision imaging agents and cancer therapies, using targeted radioactive compounds to help doctors find and treat tumours. Its strongest direct link to the Fast Growing Stocks With High Insider Ownership theme is TLX591, a Phase 3 prostate cancer therapy candidate that, alongside established diagnostics like Illuccix and BiPASS, gives Telix a clear late stage growth engine that management is actively backing.
Operations: Telix generates most of its revenue from Precision Medicine at about US$622 million, with additional contributions from Manufacturing Solutions at about US$245 million and Therapeutics at about US$9 million, partly offset by US$73 million of inter segment eliminations.
Market Cap: A$5.7 billion
Investors looking at Telix Pharmaceuticals are really looking at a radiopharma business that already has a sizeable imaging franchise, while preparing for a possible step change if TLX591’s Phase 3 prostate cancer program and other late stage assets progress as planned. Forecast double digit revenue growth and strong earnings growth expectations, together with CEO pay below peers and an experienced, mostly independent board, suggest a management team focused on scaling the business rather than just extracting cash. The stock trades below some fair value estimates and recent guidance points to group revenue above US$1 billion. At the same time, Telix is still loss making, funds itself with higher risk borrowing and faces clinical, regulatory and pricing pressures across its pipeline. The balance between that growth potential and those risks is where the real story lies.
Telix Pharmaceuticals has a radiopharma story that could be accelerating faster than many investors realise, with imaging scale and late stage therapies pulling in different directions. Get the full analysis report for Telix Pharmaceuticals
Lindian Resources (ASX:LIN)
Overview: Lindian Resources is a Perth based explorer focused on the Kangankunde Rare Earths project in Malawi, which targets rare earth concentrates used in permanent magnets for clean tech and electronics, while also holding earlier stage gold and bauxite interests in Africa and Australia. Its inclusion in the Fast Growing Stocks With High Insider Ownership screener mainly reflects the growth potential of Kangankunde as it moves from exploration toward development, rather than the smaller, less central commodities portfolio.
Market Cap: A$1.4 billion
Lindian Resources is drawing attention because Kangankunde offers rare earth exposure at a time when forecasts point to very strong earnings and revenue growth if development progresses, yet the stock still reflects all the usual early stage risks. Recent updates that confirmed its mining licence in Malawi and advanced Q4 2026 production plans, along with acquiring full ownership of the SARECO processing facility in Kazakhstan and opening a Singapore sales office, outline a potential mine to customer chain instead of a single project bet. On the other side of the ledger, the company is currently loss making, has relied on dilution and higher risk funding, and is led by a relatively new, less independent board. This means execution and financing discipline will matter as much as the geology.
Lindian Resources looks like a growth story accelerating from licence win to mine to customer chain, yet its funding and execution path still leaves big questions. Get the analyst forecasts for Lindian Resources and see where the real pressure point might be
Seeking Fresh Alternatives Before They Fly
New breakout stories can move fast and leave latecomers caught chasing momentum. Scan fresh ideas that are under the radar for now and act before the data goes stale; get in early.
- Spot steady compounders with strong cushions and let the list of solid balance sheet and fundamentals (21 results) guide you toward companies that can better handle pressure while others are dropping.
- Ride powerful macro and electrification trends by using the 9 top copper producer stocks to zero in on producers positioned for demand shifts before the crowd catches on.
- Track yield opportunities that may hold up when growth cools and use the 6 dividend fortresses to focus on payouts that could keep flying while it matters.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com